单核苷酸多态性与卡巴他赛治疗转移性去势抵抗性前列腺癌的疗效和毒性的关联。
Single-nucleotide polymorphism associations with efficacy and toxicity in metastatic castration-resistant prostate cancer treated with cabazitaxel.
机构信息
Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, 41013, Spain. European University of Madrid, Madrid, 28670, Spain.
Investigación Molecular y Traslacional en Oncología, Biomedicine Institute of Sevilla, IBiS/University Hospital Virgen del Rocío/CSIC/University of Seville, Seville, 41013, Spain.
出版信息
Pharmacogenomics. 2022 Jul;23(11):627-638. doi: 10.2217/pgs-2022-0023. Epub 2022 Jul 26.
The aim of this study was to evaluate the impact of certain single-nucleotide polymorphisms (SNPs) in cabazitaxel activity and toxicity in patients with metastatic castration-resistant prostate cancer (mCRPC). 56 SNPs in five genes (, , , and ) were genotyped in 67 mCRPC patients and their correlation with outcomes analyzed. -rs151352 (hazard ratio: 0.52) and -rs1341164 (hazard ratio: 0.53) were associated with better overall survival, and -rs1058932 with biochemical progression (odds ratio: 6.60) in multivariate analysis. -rs17327624 correlated with severe toxicity ≥grade 3 (odds ratio: 8.56) and -rs11572093 with asthenia (odds ratio: 8.12). Genetic variants in mCRPC patients could explain different outcomes with cabazitaxel. Nonetheless, the small sample size and the high number of SNPs analyzed mean that the results are only hypothesis-generating and require further validation.
本研究旨在评估 cabazitaxel 在转移性去势抵抗性前列腺癌（mCRPC）患者中的活性和毒性的某些单核苷酸多态性（SNPs）的影响。在 67 例 mCRPC 患者中对五个基因（、、、和）中的 56 个 SNP 进行了基因分型，并分析了它们与结局的相关性。-rs151352（危险比：0.52）和 -rs1341164（危险比：0.53）与总生存时间延长相关，-rs1058932 与生化进展相关（比值比：6.60），这在多变量分析中得到了验证。-rs17327624 与严重毒性≥3 级（比值比：8.56）相关，-rs11572093 与乏力（比值比：8.12）相关。mCRPC 患者的遗传变异可能解释了 cabazitaxel 的不同结局。然而，样本量小且分析的 SNPs 数量多，这意味着结果仅具有启发性，需要进一步验证。
Zotero 插件